Summary
One hundred and sixteen patients with locally advanced or metastatic breast cancer were randomized to receive CMF (cyclophosphamide 600 mg m–2 day 1 and 8 i.v., 5-fluorouracil 600 mg m–2 day 1 and 8 i.v.,, methotrexate 40 mg m–2 day 1 and 8 i.v., monthly for 6 cycles) or MM (methotrexate 30 mg m–2, mitoxantrone 6.5 mg m–2, both i.v. day 1 3-weekly for 8 cycles) as first line treatment with chemotherapy. Objective responses occurred in 17 patients out of 58 (29%) who received CMF and nine out of 58 (15%) who received MM; 95% confidence interval for difference in response rates (–1%–29%), P = 0.07. No statistically significant differences were seen in overall survival or time to progression between the two regimes although a tendency towards a shorter progression time on the MM regime must be acknowledged. There was, however, significantly reduced haematological toxicity (P < 0.001) and alopecia (P < 0.001) and fewer dose reductions and delays in patients randomized to MM. No statistically significant differences were seen between the two regimes in terms of quality of life (QOL). However, some association between QOL and toxicity was apparent overall with pooled QOL estimates tending to indicate a worsening in psychological state with increasing maximum toxicity over treatment. Despite the fact that results surrounding response rates and time to progression did not reach statistical significance, their possible compatibility with an improved outcome on CMF treatment must be borne in mind. However, MM is a well-tolerated regimen with fewer side-effects than CMF, which with careful patient management and follow-up, therefore, may merit consideration as a first-line treatment to palliate patients with metastatic breast cancer who are infirm or elderly.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aisner, J, Weinberg, V & Perloff, M et al (1987). Chemotherapy versus chemoimmunotherapy (CAFV CAFVP v CMF IMER) for metastatic carcinoma of the breast. A CALGB study. J Clin Oncol 5: 1523–1533.
Bull, JM, Tormey, DC & Shou-Hua, L et al (1978). A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657.
Canellos, GP, De Vita, VT & Gold, GL et al (1976). Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Int Med 84: 389–392.
Clavel, M & Catimel, G (1993). Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer, 29A 4: 598–604.
Cummings, FT, Gelman, R & Horton, J (1995). Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors. J Clin Oncol 3: 932–940.
De-Haes, JC, van-Knippenberg, FC & Neijt, JP (1990). Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034–1038.
EORTC: A practical guide to EORTC Studies, (1996). February
Greenspan, EM (1966). Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 33: 1–27.
Hayward, JL, Rubens, RD & Carbone, PP et al (1977). Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298.
Honig, SF (1996). Treatment of metastatic disease: hormonal therapy and chemotherapy. In:Diseases of the Breast, Harris JR, Lippman MC, Morrow M Lippincott: Philadelphia 669–734.
Jodrell, DI, Smith, IE & Mansi, JL et al (1991). A randomised comparative trial of mitoxantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer 63: 794–798.
Maguire, P & Selby, P (1989). Assessing quality of life in cancer patients. Br J Cancer 60: 437–440.
Mouridsen, H (1992). Systemic therapy of advanced disease. Drugs 44: 17–28.
Payne, SA (1992). A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505–1509.
Peto, R, Pike, MC & Armitage, P et al (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Part 2 Analysis and examples. Br J Cancer 35: 1–39.
Powles, TJ, Jones, AL & Judson, IR et al (1991). A randomised trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 64: 406–410.
Smalley, RV, Lefante, J & Bartolucci, A et al (1983). CAF v CMFVP in patients with advanced breast cancer. Breast Cancer Teat Res 3: 209–210.
Stein, RC, Bower, M & Law, M et al (1992). Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: A randomised clinical trial. Eur J Cancer 28A: 1963–1965.
Stewart, DJ, Evans, WK & Shepherd, FA et al (1997). Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 15: 1897–1905.
Tannock, IF, Boyd, NF & DeBoer, G et al (1988). A randomised trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377–1387.
Tormey, DC, Gelman, R & Band, PR et al (1982). Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 50: 1235–1244.
World Health Organisation (1979). WHO Handbook for Reporting of Cancer Treatment. WHO: Geneva
Zigmond, AS & Snaith, RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361–363.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Harper-Wynne, C., English, J., Meyer, L. et al. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer 81, 316–322 (1999). https://doi.org/10.1038/sj.bjc.6990694
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6990694
Keywords
This article is cited by
-
Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation
memo - Magazine of European Medical Oncology (2008)
-
Locally advanced breast cancer in octogenarian women
Breast Cancer Research and Treatment (2005)
-
Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
Breast Cancer Research and Treatment (2004)